Retroperitoneal lymph node dissection

Neural Networks in Urologic Oncology

Published in Raouf N.G. Naguib, Gajanan V. Sherbet, Artificial Neural Networks in Cancer Diagnosis, Prognosis, and Patient Management, 2001

C. Niederberger, D. Ridout

In the United States, 7,200 new cases of germ-cell carcinoma were diagnosed in 1997 in male patients between the ages of 15 and 34 [35]. Treatment of this disease is guided by histological type of cancer and clinical staging. Great progress has been made in the area of treatment of testicular carcinoma in the last 20 years making the prognosis of these patients very good [36]. This, in great part, is due to the use of cisplatin containing chemotherapy used to cure advanced testicular germ-cell carcinoma. Staging of testis cancer includes serum markers (alpha-fetoprotein, human chorionic gonodotrophin and lactate dehydrogenase), computed tomographic (CT) imaging of the abdomen and pelvis, and a chest X-ray film [37]. Retroperitoneal lymph node dissection (RPLND) is used in select patients depending on histology and clinical stage.

Robotic-assisted surgery for the treatment of urologic cancers: recent advances

View Article

Journal Information

Published in Expert Review of Medical Devices, 2020

Ugo Falagario, Alessandro Veccia, Samuel Weprin, Emanuel V. Albuquerque, William C. Nahas, Giuseppe Carrieri, Vito Pansadoro, Lance J. Hampton, Francesco Porpiglia, Riccardo Autorino

Robot-assisted retroperitoneal lymph node dissection (RA-RPLND) has been explored as a minimally invasive option, and it seems to have an acceptable safety profile, minimal morbidity, and short-term oncological outcomes comparable to the open approach [97]. Harris et al. compared 16 patients undergoing RA-RPLND and 21 patients who underwent L-RPLND showing equivalent results in terms of safety and perioperative outcomes [98].

Retroperitoneal lymph node dissection

Explore chapters and articles related to this topic

Neural Networks in Urologic Oncology

Robotic-assisted surgery for the treatment of urologic cancers: recent advances